Tuesday, October 11, 2016
The US Drug Enforcement Administration (DEA) has not taken action to make the herbal supplement kratom as schedule I drug, despite previously announcing its intention to do so by September 30. The delay comes as some members of Congress, as well as kratom users and researchers, have grown increasingly vociferous over the notion that the DEA would make kratom a schedule I substance, in the same class as heroin and marijuana, without allowing any public input.